Figure 2. Integrin beta3 knockout M2 macrophages have enhanced tumor-promoting function, and β3KOM macrophages promote tumor growth in part through CD8⁺ T-cells.

(A) In WT mice, at day 6 after subcutaneous B16F10 tumor establishment, 3×10⁶ IL-4-induced WT or Itgb3^−/− M2 macrophages were injected into the tumor tissue. Tumor weight was measured at day 14. (B) At day 6 and day 9 after PyMT-BO1-GFP-Luc tumor cell injection, 5×10⁶ WT or Itgb3^−/− ex vivo M2 macrophages were intracardially injected into tumor bearing mice. MFP tumor size and weight were measured. (n=6) (C) 8-week-old male WT and β3KOM mice were subcutaneously injected with 1×10⁶ B16F10 tumor cells. Anti-CD8 antibody was given by i.p. injection one day before tumor cell injection and 7 days after first antibody injection. Tumor growth was monitored and measured for 2 weeks. (D) Tumor weight measured on day 14. (Control, n=8; Anti-CD8, n=5). Data represent mean ± SEM. *P < 0.05; **P < 0.01; ***P<0.001.